Santen Reports Fiscal 2015 Consolidated Performance
May 11, 2016 03:59 ET
|
Santen Pharmaceutical Co., Ltd.
OSAKA, Japan, May 11, 2016 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (Osaka, JAPAN, Tokyo Stock Exchange Code 4536) (Santen) today announced consolidated performance for fiscal 2015 ended...
Santen Announces Assignment of Its Anti-Rheumatic Pharmaceuticals Business to Hyperion Pharma Co., Ltd.
May 12, 2015 03:53 ET
|
Santen Pharmaceutical Co., Ltd.
Disclaimer: The following document is a translation of a press release prepared in Japanese. The Japanese version is the original version and can be found on the company's website:...
Santen Reports Consolidated Performance for the Fiscal Year Ended March 31, 2015
May 12, 2015 03:52 ET
|
Santen Pharmaceutical Co., Ltd.
OSAKA, Japan, May 12, 2015 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (Tokyo Stock Exchange Code:4536) (Santen) today announced consolidated performance for fiscal 2014 (ended March 31, 2015)...
Santen Announces Approval of Ikervis for EU Marketing Authorization
March 25, 2015 04:45 ET
|
Santen Pharmaceutical Co., Ltd.
OSAKA, Japan, March 25, 2015 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. today announced it received approval of the Marketing Authorization Application (MAA) for Ikervis from the European...
European Medicines Agency Accepts Santen's Marketing Application Filing for Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis of the Posterior Segment
March 02, 2015 03:23 ET
|
Santen Pharmaceutical Co., Ltd.
OSAKA, Japan, March 2, 2015 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. announced that the European Medicines Agency (EMA) has accepted the company's Marketing Authorization Application (MAA)...
Increase of Capital for a Consolidated Subsidiary in Europe
September 25, 2014 05:31 ET
|
Santen Pharmaceutical Co., Ltd.
OSAKA, Japan, Sept. 25, 2014 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (Osaka, hereinafter "Santen") hereby announces that it was resolved at the Board of Director meeting held on September...
Santen Announces Closing of Asset Purchase Agreement With Respect to Acquisition of Ophthalmology Assets From Merck
July 02, 2014 02:32 ET
|
Santen Pharmaceutical Co., Ltd.
OSAKA, Japan, July 2, 2014 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (Osaka, Japan) (Santen) announced the closing of an asset purchase agreement ("Agreement") which was entered on May 13,...
Santen Announces the Signing of Agreement Between Merck for the Purchase of Assets in Ophthalmology
May 13, 2014 02:47 ET
|
Santen Pharmaceutical Co., Ltd.
OSAKA, Japan, May 13, 2014 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd., (Osaka, Japan) (Santen) announced today that it has entered into an Agreement with Merck & Co., Inc., (Whitehouse...
Discontinuance and Abolition of Countermeasures to Large-Scale Purchases of the Corporation's Shares (Takeover Defense Measures)
April 26, 2013 07:01 ET
|
Santen Pharmaceutical Co., Ltd.
OSAKA, Japan, April 26, 2013 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (the "Company") announces that at a meeting held today, its Board of Directors resolved to discontinue and abolish the...
FDA Approves enVista(TM), a Single-Piece Intraocular Lens, Made From the Glistening-Free, Hydrophobic, Acrylic Material Developed by AVS
June 25, 2012 04:14 ET
|
Santen Pharmaceutical Co., Ltd.
OSAKA, Japan, June 25, 2012 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. announced that Bausch + Lomb (Rochester, New York) received approval of enVista™, the first glistening-free,...